Compare SLDB & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | BLMN |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.7M | 851.9M |
| IPO Year | 2017 | 2012 |
| Metric | SLDB | BLMN |
|---|---|---|
| Price | $5.92 | $9.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 11 |
| Target Price | ★ $18.71 | $11.86 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.97 | ★ 106.71 |
| EPS | N/A | ★ 1.01 |
| Revenue | $8,094,000.00 | ★ $4,213,346,000.00 |
| Revenue This Year | N/A | $0.65 |
| Revenue Next Year | N/A | $1.66 |
| P/E Ratio | ★ N/A | $10.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $5.19 |
| 52 Week High | $11.45 | $12.63 |
| Indicator | SLDB | BLMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 48.91 |
| Support Level | $5.38 | $7.51 |
| Resistance Level | $7.26 | $9.28 |
| Average True Range (ATR) | 0.42 | 0.50 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 30.72 | 45.71 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.